• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在成功的癌症免疫治疗中,个体 T 细胞受体针对多个肿瘤相关抗原。

Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy.

机构信息

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.

Systems Immunology Research Institute, Cardiff, Wales CF14 4XN, UK.

出版信息

Cell. 2023 Aug 3;186(16):3333-3349.e27. doi: 10.1016/j.cell.2023.06.020. Epub 2023 Jul 24.

DOI:10.1016/j.cell.2023.06.020
PMID:37490916
Abstract

The T cells of the immune system can target tumors and clear solid cancers following tumor-infiltrating lymphocyte (TIL) therapy. We used combinatorial peptide libraries and a proteomic database to reveal the antigen specificities of persistent cancer-specific T cell receptors (TCRs) following successful TIL therapy for stage IV malignant melanoma. Remarkably, individual TCRs could target multiple different tumor types via the HLA A02:01-restricted epitopes EAAGIGILTV, LLLGIGILVL, and NLSALGIFST from Melan A, BST2, and IMP2, respectively. Atomic structures of a TCR bound to all three antigens revealed the importance of the shared x-x-x-A/G-I/L-G-I-x-x-x recognition motif. Multi-epitope targeting allows individual T cells to attack cancer in several ways simultaneously. Such "multipronged" T cells exhibited superior recognition of cancer cells compared with conventional T cell recognition of individual epitopes, making them attractive candidates for the development of future immunotherapies.

摘要

免疫系统的 T 细胞可以通过肿瘤浸润淋巴细胞 (TIL) 治疗靶向肿瘤并清除实体癌。我们使用组合肽文库和蛋白质组数据库,揭示了在成功进行 IV 期恶性黑色素瘤 TIL 治疗后,持续存在的癌症特异性 T 细胞受体 (TCR) 的抗原特异性。值得注意的是,单个 TCR 可以通过 HLA A02:01 限制性表位 EAAGIGILTV、LLLGIGILVL 和 NLSALGIFST 分别靶向来自 Melan A、BST2 和 IMP2 的多个不同肿瘤类型。与所有三种抗原结合的 TCR 的原子结构揭示了共享 x-x-x-A/G-I/L-G-I-x-x-x 识别基序的重要性。多表位靶向允许单个 T 细胞同时以多种方式攻击癌症。这种“多管齐下”的 T 细胞对癌细胞的识别优于传统 T 细胞对单个表位的识别,使其成为未来免疫疗法开发的有吸引力的候选者。

相似文献

1
Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy.在成功的癌症免疫治疗中,个体 T 细胞受体针对多个肿瘤相关抗原。
Cell. 2023 Aug 3;186(16):3333-3349.e27. doi: 10.1016/j.cell.2023.06.020. Epub 2023 Jul 24.
2
Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma.黑色素瘤肿瘤浸润 T 淋巴细胞的共享抗原表位及其同源 TCR 的景观图谱。
Elife. 2020 Apr 21;9:e53244. doi: 10.7554/eLife.53244.
3
T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.黑色素瘤特异性克隆性和高度寡克隆性肿瘤浸润淋巴细胞系对T细胞受体的使用情况。
Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2829-33. doi: 10.1073/pnas.91.7.2829.
4
Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.开发一种靶向癌症-睾丸抗原SSX2中HLA-A*0201限制性表位的T细胞受体,用于癌症的过继性免疫治疗。
PLoS One. 2014 Mar 28;9(3):e93321. doi: 10.1371/journal.pone.0093321. eCollection 2014.
5
Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.123例黑色素瘤患者的肿瘤浸润性T淋巴细胞对与主要HLA - A等位基因相关的共享黑色素瘤抗原的识别。
J Immunother. 2000 Jan;23(1):17-27. doi: 10.1097/00002371-200001000-00004.
6
Identification of antigenic epitopes recognized by tumor infiltrating lymphocytes in high grade serous ovarian cancer by multi-omics profiling of the auto-antigen repertoire.通过自身抗原库的多组学分析鉴定高级别浆液性卵巢癌肿瘤浸润淋巴细胞识别的抗原表位。
Cancer Immunol Immunother. 2023 Jul;72(7):2375-2392. doi: 10.1007/s00262-023-03413-7. Epub 2023 Mar 21.
7
Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers.高亲和力天然 T 细胞受体可有效介导癌症/睾丸抗原 83 阳性常见实体瘤消退。
J Immunother Cancer. 2022 Jul;10(7). doi: 10.1136/jitc-2022-004713.
8
Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy.对CD8黑色素瘤浸润淋巴细胞(TIL)识别黑色素瘤相关抗原(MAA)频率的综合分析:对免疫治疗的意义。
Eur J Immunol. 2001 Jul;31(7):2007-15. doi: 10.1002/1521-4141(200107)31:7<2007::aid-immu2007>3.0.co;2-s.
9
Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations.鉴定突变 PIK3CA 的 HLA-A*11:01 限制性新表位及其用于针对热点驱动突变的癌症免疫治疗的特异性 T 细胞受体。
Cancer Immunol Immunother. 2024 Jun 4;73(8):150. doi: 10.1007/s00262-024-03729-y.
10
Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery.针对新生抗原治疗实体恶性肿瘤:免疫手术。
Front Immunol. 2021 Jul 15;12:592031. doi: 10.3389/fimmu.2021.592031. eCollection 2021.

引用本文的文献

1
The predictive value of the neutrophil/eosinophil ratio in cancer patients undergoing immune checkpoint inhibition: a meta-analysis and a validation cohort in hepatocellular carcinoma.中性粒细胞/嗜酸性粒细胞比值在接受免疫检查点抑制治疗的癌症患者中的预测价值:一项荟萃分析及肝细胞癌验证队列研究
Front Immunol. 2025 Jul 21;16:1633034. doi: 10.3389/fimmu.2025.1633034. eCollection 2025.
2
Integrated system for screening tumor-specific TCRs, epitopes, and HLA subtypes using single-cell sequencing data.利用单细胞测序数据筛选肿瘤特异性TCR、表位和HLA亚型的集成系统。
J Immunother Cancer. 2025 Jul 31;13(7):e012029. doi: 10.1136/jitc-2025-012029.
3
Tumor-specific CD8 T cell characterization in HR breast cancer reveals an impaired antitumoral response in patients with lymph node metastasis.
HR乳腺癌中肿瘤特异性CD8 T细胞特征揭示了淋巴结转移患者抗肿瘤反应受损。
Cell Rep Med. 2025 Aug 19;6(8):102252. doi: 10.1016/j.xcrm.2025.102252. Epub 2025 Jul 28.
4
Tumor Microenvironment in Melanoma-Characteristic and Clinical Implications.黑色素瘤中的肿瘤微环境——特征与临床意义
Int J Mol Sci. 2025 Jul 15;26(14):6778. doi: 10.3390/ijms26146778.
5
Mandatory preventive vaccines for infectious diseases expressing T-cell epitopes for cancer prevention.用于预防癌症的、表达T细胞表位的传染病强制性预防性疫苗。
Infect Agent Cancer. 2025 Jul 23;20(1):50. doi: 10.1186/s13027-025-00683-x.
6
An SNP-dependent cancer-testis antigenic epitope serves as a promising immunotherapeutic target for cancer.一种单核苷酸多态性(SNP)依赖性癌胚抗原表位是一种很有前景的癌症免疫治疗靶点。
Oncoimmunology. 2025 Dec;14(1):2528110. doi: 10.1080/2162402X.2025.2528110. Epub 2025 Jul 9.
7
nuTCRacker: Predicting the Recognition of HLA-I-Peptide Complexes by αβTCRs for Unseen Peptides.nuTCRacker:预测αβT细胞受体对未知肽段的HLA-I-肽复合物的识别
Eur J Immunol. 2025 Jul;55(7):e51607. doi: 10.1002/eji.202451607.
8
PET-based immunomapping of intratumoral CD4 cells to monitor acquired resistance to checkpoint inhibitors.基于正电子发射断层扫描(PET)的肿瘤内CD4细胞免疫图谱分析以监测对检查点抑制剂的获得性耐药
Sci Adv. 2025 Jun 27;11(26):eadw1924. doi: 10.1126/sciadv.adw1924. Epub 2025 Jun 25.
9
Novel synthetic peptide-based vaccine shows promise against prostate cancer.新型合成肽基疫苗显示出对抗前列腺癌的潜力。
Mol Ther Oncol. 2025 Jun 4;33(2):201000. doi: 10.1016/j.omton.2025.201000. eCollection 2025 Jun 18.
10
Phage display enables machine learning discovery of cancer antigen-specific TCRs.噬菌体展示技术助力通过机器学习发现癌症抗原特异性T细胞受体。
Sci Adv. 2025 Jun 13;11(24):eads5589. doi: 10.1126/sciadv.ads5589. Epub 2025 Jun 11.